Takeda turns to OTCs to bolster Japanese top line
This article was originally published in Scrip
Takeda has acquired exclusive distribution rights in Japan to seven over-the-counter (OTC) products currently sold by Johnson & Johnson KK Consumer Company, in a move apparently aimed at propping up Takeda's sales top line amid weakness in its domestic prescription business.
You may also be interested in...
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.